Publications 2008
1 In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging. CT Brandt, H Simonsen, M Liptrot, LV Sogaard, JD Lundgren, C Ostergaard, N Frimodt-Moller, IJ Rowland
BMC Med Imaging. 2008 Jan 14;8(1):1 [Epub ahead of print]. abstract
2 Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. WP Bannister, L Ruiz, A Cozzi-Lepri, A Mocroft, O Kirk, S Staszewski, C Loveday, A Karlsson, A Monforte, B Clotet, JD Lundgren; EuroSIDA Study Group
AIDS. 2008 Jan 30;22(3):367 abstract
3 The role of antiretroviral therapy on the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. CJ Smith, CH Olsen, A Mocroft, JP Viard, S Staszewski, G Panos, T Staub, A Balxhult, N Vetter, JD Lundgren for the EuroSIDA study group.
AIDS. 2008 Jan 2;22(1):47-56.abstract
4 Impact of bacteremia on the pathogenesis of experimental pneumococcal meningitis. CT Brandt, D Holm, M Liptrot, C Østergaard, JD Lundgren, N Frimodt-Møller, IC Skovsted and IJ Rowland.
J Infect Dis. 2008 Jan 15;197(2):235-244. abstract
5 Procalcetonin in liver transplant patients - yet another stone turned. JU Jensen and JD Lundgren.
Crit Care Med. 2008, Jan 22;12:108 abstract
6 Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. S de Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren.
Diabetes Care. 2008 Feb 11 abstract
7 Regional differences in the risk of triple class failure in European patients starting cART after 1 January 1999. A Mocroft, A Horban, B Clotet, A d’Arminio Monforte, JR Bogner, P Aldins, T Staub, F Antunes, C Katlama, JD Lundgren for the EuroSIDA study group.
HIV Med. 2008 Jan;9(1):41-6. abstract
8 Loss to follow-up in an international, multicentre observational study. A Mocroft, O Kirk, P Aldins, A Chies, A Blaxhult, N Chentsova, N Vetter, F Dabis, J Gatell and JD Lundgren, for the EuroSIDA study group.
HIV Med. 2008 9(1):261-269 abstract
9 EACS Executive Committee.European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. JD Lundgren, M Battegay, G Behrens, S De Wit, G Guaraldi, C Katlama, E Martinez, D Nair, WG Powderly, P Reiss, J Sutinen, A Vigano;
HIV Med. 2008 Feb;9(2):72-81 abstract
10 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E l Sadr, F Dabis, S De Wit, M Law, A D´Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren.
Lancet. 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2 abstract
11 Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. AN Phillips, D Pillay, AH Miners, DE Bennett, CF Gilks, JD Lundgren.
Lancet. 2008 Apr 26;371(9622):1443-51 abstract
12 Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. CJ Smith, A Mocroft, JD Lundgren; EuroSIDA Study Group.
AIDS. 2008 May 11;22(8):997-8.
13 Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, CA Sabin, A d'Arminio Monforte, N Friis-Moller, R Weber, WM El-Sadr, P Reiss, O Kirk, P Mercie, MG Law, S De Wit, C Pradier, AN Phillips, JD Lundgren.
Clin Infect Dis. 2008 Apr 1;46(7):1101-10 abstract
14 Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, JD Lundgren, A Babiker, W El-Sadr, S Emery, B Grund, JD Neaton, J Neuhaus, AN Phillips.
J Infect Dis. 2008 Apr 15;197(8):1145-55 abstract
15 Determination of the underlying cause of death in three multicenter international HIV clinical trials. AR Lifson, WH Belloso, C Carey, RT Davey, D Duprez, WM El-Sadr, JM Gatell, DC Gey, JF HOy, EA KRum, R Nelson, DE Nixon, N Paton, C Pedersen, G Perez, RW PRice, RJ Prineas, FS Rhame, J Sampson, J Worley.
HIV Clin Trials 2008; 9:177-185 abstract
16 Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. AN Phillips, A Carr, J Neuhaus, F Visnegarwala, R Prineas, WJ Burman, I Williams, F Drummond, D Duprez, WH Belloso, FD Goebel, B Grund, A Hatzakis, J Vera, JD Lundgren.
Antivir Ther. 2008;13(2):177-87 abstract
17 Transmitted drug resistance and association with virological and CD4 cell count response to combination antiretroviral therapy in EuroSIDA. WP Bannister, A Cozzi-Lepri, B Clotet, A Mocroft, J Kjær, P Reiss, V von Wyl, A Lazzarin, C Katlama, AN Phillips, L Ruiz, JD Lundgren and the EuroSIDA study group.
J Acquir Immune Defic Syndr. 2008 Jun 9. [Epub ahead of print] abstract
18 Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. K Deforche, A Cozzi-Lepri, K Theys, B Clotet, RJ Camacho, J Kjær, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren, and A-M Vandamme on behalf of the EuroSID Study Group.
Antivir Ther. 13:399-407 abstract
19 State of the Science Conference. Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS Executive Summary. SK Grinspoon, C Grunfeld, DP Kotler, JS Currier, JD Lundgren, MP Dubé, SE Lipshultz, PY Hsue, K Squires, M Schambelan, PW Wilson, KE Yarasheski, CM Hadigan, JH Stein, RH Eckel.
Circulation. 2008 Jun 19. [Epub ahead of print] abstract
20 Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy.JS Currier, JD Lundgren, A Carr, D Klein, CA Sabin, PE Sax, JT Schouten, M Smieja; for Working Group 2.
Circulation. 2008 Jun 19. [Epub ahead of print] abstract
21 Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. M Schambelan, PW Wilson, KE Yarasheski, WT Cade, VG Dávila-Román, RB Sr D'Agostino, TA Helmy, M Law, KE Mondy, S Nachman, LR Peterson, SW Worm; for Working Group 5.
Circulation. 2008 Jun 19. [Epub ahead of print]
22 Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients. JH Stein, CM Hadigan, TT Brown, E Chadwick, J Feinberg, N Friis-Møller, A Ganesan, MJ Glesby, D Hardy, RC Kaplan, P Kim, J Lo, E Martinez, JM Sosman; for Working Group 6.
Circulation. 2008 Jun 19. [Epub ahead of print]
23 Indicator disease-guided testing for HIV--the next step for Europe? B Gazzard, N Clumeck, A d'Arminio Monforte, JD Lundgren.
HIV Med. 2008 Jul;9 Suppl 2:34-40. abstract
24 Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. D Podlekareva, A Mocroft, O Kirk, P Reiss, P Aldins, C Katlama, H Kovari, HJ Stellbrink, A D'Arminio Monforte, JD Lundgren.
Scand J Infect Dis. 2008 Jun 18:1-6. [Epub ahead of print] abstract
25 Pneumonia in HIV-Infected Persons: Increased Risk with Cigarette Smoking and Treatment Interruption.. FM Gordin, MP Roediger, PM Girard, JD Lundgren, JM Miro, A Palfreeman, MC Rodriguez-Barradas, MJ Wolff, PJ Easterbrook, K Clezy, LN Slater.
Am J Respir Crit Care Med. 2008 Jul 10. [Epub ahead of print] abstract
26 The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. JU Jensen, B Lundgren, L Hein, T Mohr, PL Petersen, LH Andersen, AO Lauritsen, S Hougaard, T Mantoni, B Bømler, KJ Thornberg, K Thormar, J Løken, M Steensen, P Carl, JA Petersen, H Tousi, P Søe-Jensen, M Bestle, S Hestad, MH Andersen, P Fjeldborg, KM Larsen, C Rossau, CB Thomsen, C Ostergaard, J Kjaer, J Grarup, JD Lundgren.
BMC Infect Dis. 2008 Jul 13;8:91. abstract
27 Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks. J Kjær, L Høj, Z Fox, JD Lundgren.
HIV Med. 2008 Jul 2. [Epub ahead of print] abstract
28 Optimal HIV testing and earlier care:the way forward in Europe. T Coenen, J Lundgren, J Lazarus, S Matic.
HIV Med. 2008 JUl;9 Suppl 2:1-5
29 Incidence of abacavir hypersensitivity reactions in EuroSIDA. WP Bannister, N Friis-Møller, A Mocroft, J-P Viard, J van Lunzen, O Kirk, P Gargalianos, D Bánhegyi, A Chiesi, JD Lundgren, and the EuroSIDA study group.
Antivir Ther. 2008;13(5):687-96 abstract
30 The clinical application of the EuroSIDA risk score. J Reekie, A Mocroft, O Kirk and J D Lundgren.
AIDS & Hepatitis digest. 2008; 126:1-5
31 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. The SMART/INSIGHT and the D:A:D study groups. Writing committee: JD Lundgren, J Neuhaus, A Babiker, D Cooper, D Duprez, W El-Sadr, S Emery, F Gordin, J Kowalska, A Phillips, RJ Prineas, P Reiss, C Sabin, R Tracy, R Weber, B Grund and JD Neaton.
AIDS.2008, 22:F17-F24 abstract
32 Risk for opportunistic disease and death after reinitiating continous antiretroviral therapy in patients with HIV previously receiving episodic therapy. A randomized trial. The SMART study group. Writing group: WM El-Sadr, B Grund, J Neuhaus, A Babiker, CJ Cohen, J Darbyshire, S Emery, JD Lundgren, A Phillips and JD Neaton.
Ann Intern Med. 2008;149:289-299 abstract
33 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. A Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
AIDS. 2008 Oct 18;22(16):2143-53 abstract
34 The elusive search for an HIV vaccine-And what to do meanwhile. JV Lazarus, A Häggblom, L Kirkegaard, JD Lundgren, S Matic.
Vaccine. 2008 Sep 24.
35 Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. LH Kuller, R Tracy, W Belloso, SD Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, J Neuhaus, D Nixon, NI Paton, JD Neaton for the INSIGHT SMART Study Group.
PLoS Med. 2008 Oct 21;5(10):e203. abstract
36 The EuroSIDA study: regional differences in HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe - a review of published results. D Podlekareva, W Bannister, A Mocroft, L Abrosimova, I Karpov, JD Lundgren, O Kirk for the EuroSIDA study group
Cent Eur J Public Health. 2008 Sep;16(3):99-105.abstract
37 Detection of HIV drug resistance during antiretrovrial treatment and clinical progression in a large European cohort study. A Cozzi-Lepri, AN Phillips, B Clotet, A Mocroft, L Ruiz, O Kirk, A Lazzarin, A Wiercinska-Drapalo, A Karlsson, JD Lundgren for the EuroSIDA Study Group.
AIDS. 2008 Oct 18;22(16):2187-98. abstract
38 Cardiovascular risk in HIV Disease. Edited by JS Currier and JD Lundgren.
Curr. Opin in HIV & AIDS. 3(3):205-251, May 2008
39 Guidelines for managing cardiovascular risk: an evolving area. JS Currier, JD Lundgren
Curr. Opin in HIV & AIDS. 3(3):205-206, May 2008
40 Conventional cardiovascular risk factors in HIV Infection: how conventional are they? C Sabin, SW Worm
Curr. Opin in HIV & AIDS. 3(3):214-219, May 2008
41 Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. N Friis-Møller, M Smieja, D Klein
Curr. Opin in HIV & AIDS. 3(3):220-225, May 2008
42 EuroSIDA: a prospective observational study of chronic HIV Infection across the European Continent. JD Lundgren, O Kirk, A Mocroft
[Bookchapter from “A Decade og HAART”, published by Oxford University Press. p.195-212]
43 Response to combination antiretroviral therapy: variation by age. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study group.
AIDS. 22(12):1463-1473, July 31, 2008 abstract
44 The ART Cohort Collaboration: Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? Writing committee: Michael J. Mugavero, Margaret May, Ross Harris, Michael S. Saag, Dominique Costagliola, Matthias Egger, Andrew Phillips, Huldrych Günthard, Francois Dabis, Robert Hogg, Frank de Wolf, Gerd Fatkenheuer, John Gill, Amy Justice, Antonella D'Arminio Monforte, Fiona Lampe, Jose Maria Miró, Schlomo Staszewski , Mari Kitahata and Jonathan A C Sterne. AIDS 2008; 22: 2481-2492.
45 The ART Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Writing committee: Hogg, R., Lima V., Sterne, J.A.C. Grabar, S., Battegay, M., Bonarek, M., D’Arminio Monforte, A., Esteve, A., Gill, M.J., Harris, R., Justice, A., Hayden, A., Lampe, F., Mocroft, A., Mugavero, M.J., Staszewski, S., Wasmuth J.C., van Sighem, A., Kitahata, .M, Guest, J., Egger, M. and May, M. Lancet 2008; 372: 293-299.
46 The role of HIV in serious diseases other than AIDS. Phillips AN, Neaton J, Lundgren JD. AIDS. 2008 Nov 30;22(18):2409-18. Review. PubMed PMID: 19005264; PubMed Central PMCID: PMC2679976.
47 Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group. AIDS. 2008 Nov 12;22(17):2381-90. PubMed PMID: 18981778.
48 Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group. AIDS. 2008 Nov 12;22(17):2279-89. PubMed PMID: 18981767.
49 Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, Lundgren JD; SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Clin Infect Dis. 2008 Dec 1;47(11):1468-75. PubMed PMID: 18959492.
50 ART failure and strategies for switching ART regimens in Europe. Eramova I, Munz M, Lundgren J, Matic S. Cent Eur J Public Health. 2008 Sep;16(3):141-4. PubMed PMID: 18935782.
51 Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2008 Nov 1;198(9):1337-44. PubMed PMID: 18767985.
52 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. J Infect Dis. 2008 Apr 15;197(8):1133-44. PubMed PMID:18476292.
53 Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A; INITIO Trial International Co-ordinating Committee; HAMA study coordination team. HIV Med. 2008 Feb;9(2):101-10. PubMed PMID: 18257772.
54 European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. HIV Med. 2008 Feb;9(2):65-71. PubMed PMID: 18257769.
55 Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M. Antivir Ther. 2008;13(8):959-67. PubMed PMID: 19195321.
56 Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F,Miró JM, Staszewski S, Sterne JA. AIDS. 2008 Nov 30;22(18):2481-92. PubMed PMID:19005271.
57 Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. Mussini C, Manzardo C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C; Late Presenter Investigators. AIDS. 2008 Nov 30;22(18):2461-9. PubMed PMID: 19005269.
58 The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Review. PubMed PMID: 18935770.
Updated: 16 Sep 2009